Abstract | INTRODUCTION:
Meige syndrome is a segmental form of dystonia where botulinum toxins are the preferred treatment option. However, its invasive nature, treatment costs, partial responsiveness, and benefit duration are some of their limitations. METHODS: RESULTS: A dramatic response was obtained in all subjects during the first weeks of treatment. Aripiprazole mean ± SD daily dose was 7.9 ± 3.6 mg. Three subjects developed parkinsonism related to aripiprazole treatment; the former improved after reducing the dosage, without significant worsening of cranial dystonia. After a mean ± SD follow-up of 2.0 ± 0.7 years, clinical benefit persists over time, with a mean percentage reduction of Unified Dystonia Rating Score of 75.6% ± 8.4%. CONCLUSIONS:
|
Authors | Michel Sáenz-Farret, Carlos Zúñiga-Ramírez |
Journal | Clinical neuropharmacology
(Clin Neuropharmacol)
2021 Nov-Dec 01
Vol. 44
Issue 6
Pg. 225-228
ISSN: 1537-162X [Electronic] United States |
PMID | 34456230
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
|
Topics |
- Aripiprazole
(therapeutic use)
- Dystonia
- Humans
- Meige Syndrome
(chemically induced, drug therapy)
- Treatment Outcome
|